2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
2013
Beta prime regression with application to risky behavior frequency screening
Tulupyev A, Suvorova A, Sousa J, Zelterman D. Beta prime regression with application to risky behavior frequency screening. Statistics In Medicine 2013, 32: 4044-4056. PMID: 23616229, PMCID: PMC3789864, DOI: 10.1002/sim.5820.Peer-Reviewed Original Research
2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
2010
Metachronous Primary Melanoma and Lymphoma
McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaTumor RegistryYale-New Haven HospitalConnecticut Tumor RegistryEffect of treatmentStudy patientsCutaneous melanomaSurvival differencesPrimary melanomaLymphomaPatientsMelanomaViral inductionDiagnosisGenetic mutationsSurvivalRegistryLonger intervalsMalesGender comparisonsFurther researchImmunosuppressionMalignancyNeoplasmsHospital
2006
Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.Peer-Reviewed Original ResearchConceptsT3-4 tumour stageUse of PORTN2 nodal diseaseEnd Results (SEER) databasePostoperative radiotherapyCell lung cancerLymph nodesNodal diseaseResults databaseTumor stageLung cancerNode stageStage IIHigher American Joint CommitteeAdvanced node stageAmerican Joint CommitteePopulation-based cohortLarger tumor sizeMedian followPerioperative mortalityMale sexTumor sizeSubset analysisCancer stageInclusion criteria
2003
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
Tangir J, Zelterman D, Ma W, Schwartz P. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics And Gynecology 2003, 101: 251-7. PMID: 12576247, DOI: 10.1016/s0029-7844(02)02508-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyFemaleFertilityFollow-Up StudiesGerminomaHumansInfertility, FemaleLogistic ModelsMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingOvarian NeoplasmsOvariectomyPregnancyProbabilityRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeConceptsMalignant germ cell tumorsGerm cell tumorsFertility-preserving surgeryCell tumorsFollow-upReproductive functionInternational Federation of Gynecology and Obstetrics (FIGO) stage ITreated with other combinationsStage IIIStage IFIGO stage IFertility-preserving treatmentMedian follow-upLoss of follow-upActinomycin DCase series analysisReproductive function of womenFollow-up informationConservative surgeryNo chemotherapyCongenital anomaliesFunction of womenChemotherapyTumorCisplatin
2002
Statistical Inference for Familial Disease Clusters
Yu C, Zelterman D. Statistical Inference for Familial Disease Clusters. Biometrics 2002, 58: 481-491. PMID: 12229982, DOI: 10.1111/j.0006-341x.2002.00481.x.Peer-Reviewed Original Research
2000
Patterns of response to acute naloxone infusion in Tourette's syndrome
van Wattum P, Chappell P, Zelterman D, Scahill L, Leckman J. Patterns of response to acute naloxone infusion in Tourette's syndrome. Movement Disorders 2000, 15: 1252-1254. PMID: 11104215, DOI: 10.1002/1531-8257(200011)15:6<1252::aid-mds1030>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsTourette syndromeTic behaviorsOpioid antagonist naloxoneDose-related effectsDose-response effectExpression of TSRandomized dosesAntagonist naloxoneNaloxone infusionOpioid receptorsLow doseHigh doseEarlier pilot studyPattern of responseSyndromeNaloxoneTS subjectsPilot studySignificant decreaseSignificant increaseDoseDifferent dosagesOpposite effectSubjectsVideotaped recordings
1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence groupDownregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories
Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu M. Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. The American Journal Of Surgical Pathology 1999, 23: 678-685. PMID: 10366150, DOI: 10.1097/00000478-199906000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdultAgedCarcinoma, PapillaryCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesDisease-Free SurvivalDown-RegulationFemaleHumansImmunoenzyme TechniquesKi-67 AntigenMaleMicrotubule-Associated ProteinsMiddle AgedPrognosisThyroid NeoplasmsTumor Suppressor ProteinsConceptsKi67/MIB1 labeling indexLow p27Kip1 expressionMIB1 labeling indexThyroid carcinomaFollicular carcinomaP27Kip1 expressionPathologic featuresPrognostic groupsTumor differentiationLabeling indexFavorable pathologic featuresKi67/MIB1Unfavorable pathologic featuresAdverse prognostic factorLarger tumor sizeFollicular cell originDownregulation of p27Kip1Valuable prognostic indicatorCellular proliferationCellular proliferation patternsCyclin-dependent kinase inhibitor p27Kip1High proliferative rateLow p27Kip1Prognostic factorsTumor sizeAssessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation
Salloum E, Tanoue L, Wackers F, Zelterman D, Hu G, Cooper D. Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 1999, 17: 171-180. PMID: 10099655, DOI: 10.3109/07357909909021418.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyDacarbazineDose-Response Relationship, RadiationDoxorubicinEvaluation Studies as TopicFemaleFollow-Up StudiesHeartHodgkin DiseaseHumansLungMaleMechlorethamineMiddle AgedPhysical ExertionPrednisoneProcarbazineRadiotherapy, AdjuvantRemission InductionRespiratory Function TestsVinblastineVincristineConceptsLeft ventricular ejection fractionMOPP/ABVDHodgkin's diseaseAdult patientsPulmonary functionInvolved-field radiation therapyFEV1/FVC ratioIU/m2Pulmonary function testsVentricular ejection fractionVital capacity valuesTotal lung capacityMediastinal irradiationPulmonary symptomsDiastolic functionModality therapyEjection fractionCardiopulmonary functionFunction testsFVC ratioStudy abnormalitiesCigarette smokersCardiac toxicityLung capacitySuch therapy
1998
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineFemaleHeartHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLungLymphoma, Non-HodgkinMaleMelphalanMiddle AgedNeutropeniaNeutrophilsPodophyllotoxinRespiratory Function TestsRetrospective StudiesVentricular Function, LeftConceptsHigh-dose chemotherapyPulmonary function testsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationProgenitor cell transplantationPBPC transplantationDose chemotherapyVital capacityCell transplantationAutologous peripheral blood progenitor cell transplantationAbnormal pulmonary function testsVentricular ejection fraction valuesHigh-dose therapyTotal lung capacityTime of reevaluationEjection fraction valuesEquilibrium radionuclide angiographyMediastinal irradiationAdditional therapyComplete remissionDose therapyPulmonary symptomsExpiratory volumePulmonary functionPFT values
1997
Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChildFemaleGallium RadioisotopesHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRadiotherapy, AdjuvantTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsNegative 67Ga scanPositive 67Ga scanTime of diagnosisManagement of patientsHodgkin's diseaseStage IIIStage IPredictive valueGallium scanGross residual diseaseEnd of therapyNegative predictive valueLow predictive valueModality therapyProgressive diseaseResidual diseasePositive scansRadiation therapyPatientsTherapyDiseaseScansTreatmentDiagnosisChemotherapy
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissionsTuberculosis in physicians: Compliance with surveillance and treatment
Ramphal-Naley L, Kirkhorn S, Lohman W, Zelterman D. Tuberculosis in physicians: Compliance with surveillance and treatment. American Journal Of Infection Control 1996, 24: 243-253. PMID: 8870908, DOI: 10.1016/s0196-6553(96)90056-5.Peer-Reviewed Original ResearchConceptsPositive skin test resultsSkin test resultsTuberculin skin test resultsPositive Mantoux test resultSkin test conversionMantoux test resultsSkin testingTB surveillanceFull-time physiciansStaff physiciansPoor complianceTest conversionLow prevalenceNegative tuberculin skin test resultsPositive tuberculin skin test resultsHealth AdministrationResident physiciansTuberculin skin test statusAnnual skin testingHalf of physiciansHealth care workersDepartment of PathologyThird of physiciansTuberculosis skin testingOccupational Safety
1994
Prevalence of microfissures in the human temporal bone: A report of 1000 temporal bones
Moreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of microfissures in the human temporal bone: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 741-746. PMID: 8196450, DOI: 10.1288/00005537-199406000-00015.Peer-Reviewed Original ResearchPrevalence of carotid canal dehiscence in the human middle ear: A report of 1000 temporal bones
Moreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of carotid canal dehiscence in the human middle ear: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 612-618. PMID: 8189992, DOI: 10.1002/lary.5541040515.Peer-Reviewed Original ResearchPrevalence of facial canal dehiscence and of persistent stapedial artery in the human middle ear: A report of 1000 temporal bones
Moreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of facial canal dehiscence and of persistent stapedial artery in the human middle ear: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 309-320. PMID: 8127188, DOI: 10.1288/00005537-199403000-00012.Peer-Reviewed Original ResearchConceptsPersistent stapedial arteryFacial canal dehiscenceCanal dehiscenceTemporal boneStapedial arteryFacial canalPrevalence of bilateralityOval window areaVascular anomaliesCommon siteFirst histological studyHistological studyMiddle earPrevalenceDehiscenceArteryHuman middle earBoneCanalBilaterality
1991
Age-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic Study
Ruah C, Schachern P, Zelterman D, Paparella M, Yoon T. Age-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic Study. JAMA Otolaryngology - Head & Neck Surgery 1991, 117: 627-634. PMID: 2036184, DOI: 10.1001/archotol.1991.01870180063013.Peer-Reviewed Original ResearchConceptsTympanic membraneAge-related morphologic changesFull-term infantsOtoscopic appearancePathologic evidenceWeeks' gestationOtologic diseaseTemporal boneOlder ageMorphologic changesElectron microscopic studyNormal changesGestationFirst yearMicroscopic studyPatientsInfantsVascularityYearsCellularityDisease